Cornell Scientists Achieve Reversible Male Contraception That Halts Sperm Production Without Hormones

Scientists at Cornell University have taken what researchers are calling the most significant step in decades toward a safe, reversible, nonhormonal male contraceptive, reporting in the Proceedings of the National Academy of Sciences that they successfully halted sperm production in male mice using a small-molecule compound — with fertility fully restored within six weeks of stopping treatment.

The research, published April 7 and led by Paula Cohen, professor of genetics at Cornell's College of Veterinary Medicine and director of the Cornell Reproductive Sciences Center, focused on a compound called JQ1, a small molecule inhibitor originally developed as a research tool for studying cancer and inflammatory disease. Cohen's team, which spent six years on the work, found that JQ1 disrupts a specific stage of meiosis — the cellular process that produces sperm cells — in a way that completely stops sperm production without permanently damaging the stem cells responsible for long-term fertility.

In the mouse study, males treated with JQ1 for three weeks produced zero sperm. When the compound was discontinued, normal sperm production resumed within six weeks. The male mice subsequently fathered healthy offspring with no observable abnormalities, demonstrating that the contraceptive effect was entirely reversible. Critically, the mechanism targets sperm production rather than hormone levels, which means the approach avoids the testosterone suppression and resulting side effects — mood changes, reduced libido, bone density loss — that have derailed several hormonal male contraceptive programs over the past three decades.

Co-first authors Stephanie Tanis and Leah Simon (Ph.D. '25), both now postdoctoral researchers at the University of Colorado, contributed to the study alongside a team that Cohen said has been working on this problem with little external recognition. "We're practically the only group that's pushing the idea that contraception targets in the testis are a feasible way to stop sperm production," Cohen said. "The field has been focused on hormonal approaches for so long."

The specific target of JQ1 is prophase 1, the stage of meiosis during which the chromosomes of sperm precursor cells undergo crossing over and recombination. By blocking activity at this checkpoint, the compound stalls the production line for new sperm cells. The stem cells that replenish the sperm supply are spared entirely, which is why fertility returns once treatment stops.

JQ1 itself cannot be used in humans because it crosses the blood-brain barrier and produces neurological side effects that would make it unsuitable as a consumer therapeutic. Cohen's next step is to develop derivative compounds that preserve JQ1's meiosis-blocking properties while eliminating its neurological activity. She said she plans to launch a company within two years to advance the work toward human trials.

If successful, a human male contraceptive based on this approach would likely be delivered as a quarterly injection or a patch, Cohen said. That profile would compare favorably to many existing hormonal contraceptives used by women, which require daily pills or monthly injections. The global market for male contraceptives beyond condoms and vasectomies is effectively zero today, leaving women to bear a disproportionate share of the medical burden of contraception.

Reproductive health experts not involved in the study called the results promising but cautioned that the path from mouse model to approved human drug typically takes 10 to 15 years and frequently encounters setbacks. Still, they said the clarity of the mechanism and the reversibility of the effect gave this approach more theoretical credibility than many that have failed earlier in development.